Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Non-Executive Director Stephen Diggle buys 2.5 million shares via Vulpes Life Sciences Fund and Vulpes Testudo Fund at average 45.5 pence, worth GBP1.1 million, on Tuesday. Diggle now is interested in 14.7 million shares, a 14.7% stake.
Current stock price: 43.30p, up 0.7% on Thursday
Year-to-date change: down 48%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Oxford Biodyn (OBD)